Driving Clinical Research While Enhancing Patient Experience

Q: What is the scope of AbbVie's operations in Mexico, and how does the company help drive scientific development in the country?

A: AbbVie has operated as an independent biopharmaceutical enterprise for 13 years, building upon a century-long legacy in Mexico formerly tied to Abbott. We specialize in complex therapeutic areas, including immunology, oncology, neuroscience, eye care, and medical aesthetics. In Mexico, we employ about 350 professionals across commercial and functional operations, alongside a specialized scientific center staffed by nearly 100 healthcare professionals. This scientific center drives local clinical development, aligning with national healthcare priorities and serving regional and global scientific initiatives.

Q: What is AbbVie Mexico’s primary strategy for sustaining long-term growth?

A: Mexico has consistently served as a strategic, high-priority market for AbbVie both in Latin America and globally. Healthcare leadership and delivery are evolving rapidly, requiring comprehensive collaboration across all ecosystem stakeholders, including regulatory authorities, healthcare providers, academia, civil society, and industry. Our central focus remains the patient experience. From structural drug packaging design to clinical development, every operational decision is calibrated to improve patient outcomes, enhance adherence, and support a sustainable healthcare system.

Our strategy centers on aligning global growth drivers with local healthcare needs to expand access to medical innovation. A critical pillar of this long-term strategy is clinical research as a driver of evidence generation. By expanding clinical trials, fostering local research talent, and strengthening institutional research capabilities, we generate evidence-based solutions that enhance clinical decision-making. Sustained growth relies on a unified approach where public, private, academic, and civil entities collaborate to deliver treatments to patients when needed.  

Q: In light of global trends toward decentralized clinical trials and AI-driven R&D, how does Mexico maintain its competitive edge as a clinical research hub?

A: Maintaining competitiveness requires predictability and consistency, particularly regarding regulatory timelines and trial approval processes. Demonstrating predictable execution builds headquarters' confidence to allocate additional global trials to Mexico. The country possesses unique structural advantages, including ethnic diversity, robust medical institutions, high clinical capability among researchers, and active regulatory engagement. Ensuring efficiency and consistency across these variables allows Mexico to compete effectively with other emerging global clinical trial destinations.

Q: How is AbbVie investing in organizational culture and talent retention in Mexico?

A: Talent attraction and retention are foundational to our operations. Mexico boasts exceptionally high-caliber scientific and managerial talent. Our dedicated scientific center in Mexico, which grew from 30 professionals to nearly 100, provides analytical and operational support locally, across Latin America, and internationally. By offering clear career progression, visibility, and a fulfilling workplace environment, we enable professionals to achieve personal and corporate objectives, reinforcing Mexico’s standing as a key talent hub for AbbVie globally.

Q: How do you balance major clinical investments with local operational execution to accelerate patient access to therapies?

A: Healthcare systems are navigating complex chronic disease burdens and broad access demands. Addressing these challenges requires modern leadership that evaluates the entire patient journey rather than isolated therapeutic interventions. Clinical research provides valuable data across this journey, enabling us to design integrated care models. By balancing early-stage clinical research with structured local execution, we establish sustainable access frameworks that deliver consistent value across both public and private health sectors.

Q: How do regulatory processes under COFEPRIS impact your ability to launch innovative therapies in Mexico?

A: Bringing complex therapies to market requires continuous dialogue, regulatory alignment, and shared commitment among all health sector participants. We observe ongoing engagement from regulatory authorities to streamline research and approval pathways. Navigating regulatory frameworks involves rigorous compliance, clear communication, and operational consistency. We work alongside regulatory bodies to advance therapy approvals and secure timely patient access, maintaining transparent communication and adhering strictly to established guidelines.

Q: How does AbbVie collaborate with medical societies, patient groups, and regulatory bodies to strengthen the overall healthcare ecosystem?

A: Collaboration is an ongoing, organization-wide responsibility. We actively engage with medical societies, civil organizations, and health authorities through open dialogue and mutual respect for institutional processes. Strengthening the healthcare ecosystem requires active listening to understand the unique requirements of each stakeholder. By identifying common goals, we build functional bridges that facilitate the safe and efficient delivery of innovative medicines to patients.

Q: How is AbbVie’s market share distributed between Mexico's public and private healthcare sectors?

A: Our participation is balanced between the public and private sectors. This distribution reflects the composition of our diverse product portfolio across our five core therapeutic divisions, where individual therapies exist at varying stages of their lifecycle. Maintaining a balanced presence across both sectors ensures broad demographic reach and operational stability.

We continuously explore tailored access models adapted to specific therapeutic portfolios and institutional requirements. Each therapeutic area presents distinct health economic dynamics. By actively engaging health authorities and institutional partners to understand their operational and budgetary priorities, we evaluate flexible proposals that align with institutional goals while supporting long-term healthcare system sustainability.

Q: How is AbbVie adapting its engagement strategies for younger demographic groups and digital-native patient populations?

A: Patient demographics and digital engagement expectations vary significantly across therapeutic areas. Addressing new generations of patients requires understanding how digital tools and information channels influence health seeking behavior. Our focus extends beyond drug delivery to supporting therapy adherence and comprehensive disease management. By providing integrated healthcare solutions that support patients throughout their care journey, we ensure that treatment plans achieve their intended clinical efficacy.

Q: How does multidisciplinary care across different medical specialties influence treatment decisions within your key therapeutic areas?

A: Multidisciplinary treatment models are becoming standard practice across both public and private institutions. Complex conditions in fields like immunology or oncology frequently require coordinated management across multiple medical specialties. AbbVie supports this integrated approach by facilitating interdisciplinary clinical dialogue and providing comprehensive evidence. Ensuring seamless communication among specialists leads to more holistic diagnostic and treatment decisions, ultimately producing better patient outcomes.

Q: What are AbbVie Mexico’s primary commercial and strategic priorities through 2026 and heading into 2027?

A: Our immediate priority is successfully finalizing active institutional procurement cycles while ensuring seamless continuity into upcoming public health purchasing programs. Strategically, we remain focused on expanding our clinical research footprint, achieving planned clinical milestones, and consolidating market leadership across our core therapeutic lines, specifically immunology, oncology, and neuroscience. Across both public and private channels, our goal is to maintain operational excellence and deliver innovative treatment options to Mexican patients.